The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: A single-institution study

European Journal of Cancer

Volumn 47, Issue 1, 2011, Pages 65-73

  Caussa, Lucas ^a   Kirova, Youlia M ^a   Gault, Nathalie ^a   Pierga, Jean Yves ^a   Savignoni, Alexia ^a   Campana, Franois ^a   Dendale, Rémi ^a   Fourquet, Alain ^a   Bollet, Marc A ^a  

^a INSTITUT CURIE   (France)

Author keywords

Breast cancer; Concomitant treatment; Radiotherapy; Trastuzumab

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; GONADORELIN DERIVATIVE; NAVELBINE; TAMOXIFEN; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; ESOPHAGITIS; FIBROSIS; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HUMAN; LYMPHEDEMA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PARESIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DERMATITIS; RADIATION DOSE; SIDE EFFECT; SKIN TOXICITY; SYSTOLIC DYSFUNCTION; TELANGIECTASIA; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DRUG ERUPTIONS; FEMALE; HEART DISEASES; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; RADIOTHERAPY; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 78650416030     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.08.013     Document Type: Article

References (42)

1. D.J. Slamon, G.M. Clark, and S.G. Wong Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 4785 1987 177 182
2. D.J. Slamon, W. Godolphin, and L.A. Jones Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 4905 1989 707 712
3. D.J. Slamon, B. Leyland-Jones, and S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 11 2001 783 792
4. E.H. Romond, E.A. Perez, and J. Bryant Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 16 2005 1673 1684
5. I. Smith, M. Procter, and R.D. Gelber 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 369 9555 2007 29 36
6. H. Joensuu, P.L. Kellokumpu-Lehtinen, and P. Bono Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer N Engl J Med 354 8 2006 809 820
7. J. Huang, L. Barbera, M. Brouwers, G. Browman, and W.J. Mackillop Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review J Clin Oncol 21 3 2003 555 563
8. K. Liang, Y. Lu, and W. Jin Sensitization of breast cancer cells to radiation by trastuzumab Mol Cancer Ther 2 11 2003 1113 1120
9. M.J. Piccart-Gebhart, M. Procter, and B. Leyland-Jones Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 16 2005 1659 1672
10. M. Clarke, R. Collins, and S. Darby Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials Lancet 366 9503 2005 2087 2106
11. C.W. Elston, and I.O. Ellis Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 19 5 1991 403 410
12. A.L. Balaton, J.M. Coindre, and F. Collin Recommendations for the immunohistochemical evaluation of hormone receptors on paraffin sections of breast cancer. Study Group on Hormone Receptors using Immunohistochemistry FNCLCC/AFAQAP. National Federation of Centres to Combat Cancer/French Association for Quality Assurance in Pathology Ann Pathol 16 2 1996 144 148
13. J.R. Harris, M.B. Levene, G. Svensson, and S. Hellman Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast Int J Radiat Oncol Biol Phys 5 2 1979 257 261
14. A. Trotti, A.D. Colevas, and A. Setser CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 13 3 2003 176 181
15. J.Y. Pierga, F.C. Bidard, and C. Mathiot Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial Clin Cancer Res 14 21 2008 7004 7010
16. Roche H, Fumoleau P, Spielmann M, et al. Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 trial. J Clin Oncol 2006.
17. M.A. Bollet, B. Sigal-Zafrani, and L. Gambotti Pathological response to preoperative concurrent chemo-radiotherapy for breast cancer: results of a phase II study Eur J Cancer 42 14 2006 2286 2295
18. Y.M. Kirova, N. Fournier-Bidoz, and V. Servois How to boost the breast tumor bed? A multidisciplinary approach in eight steps Int J Radiat Oncol Biol Phys 72 2 2008 494 500
19. S. Alran, Y. De Rycke, and V. Fourchotte Validation and limitations of use of a breast cancer nomogram predicting the likelihood of non-sentinel node involvement after positive sentinel node biopsy Ann Surg Oncol 14 8 2007 2195 2201
20. F. Campana, Y.M. Kirova, and J.C. Rosenwald Breast radiotherapy in the lateral decubitus position: a technique to prevent lung and heart irradiation Int J Radiat Oncol Biol Phys 61 5 2005 1348 1354
21. M.A. Bollet, F. Campana, and Y.M. Kirova Breast radiotherapy in women with pectus excavatum (funnel chest): is the lateral decubitus technique an answer? A dosimetric study Br J Radiol 79 946 2006 785 790
22. ICRU. Report 50: Prescribing, recording, and reporting photon beam therapy. Washington (DC): International Commission on Radiation Units and Measurements; 1993.
23. C.W. Hurkmans, J.H. Borger, and L.J. Bos Cardiac and lung complication probabilities after breast cancer irradiation Radiother Oncol 55 2 2000 145 151
24. F.M. Kong, E.E. Klein, and J.D. Bradley The impact of central lung distance, maximal heart distance, and radiation technique on the volumetric dose of the lung and heart for intact breast radiation Int J Radiat Oncol Biol Phys 54 3 2002 963 971
25. Y.M. Kirova, F. Campana, and N. Fournier-Bidoz Postmastectomy electron beam chest wall irradiation in women with breast cancer: a clinical step toward conformal electron therapy Int J Radiat Oncol Biol Phys 69 4 2007 1139 1144
26. Y.M. Kirova, V. Servois, and F. Campana CT-scan based localization of the internal mammary chain and supra clavicular nodes for breast cancer radiation therapy planning Radiother Oncol 79 3 2006 310 315
27. Y.M. Kirova, P. Castro Pena, and R. Dendale Simplified rules for everyday delineation of lymph node areas for breast cancer radiotherapy Br J Radiol 83 992 2010 683 686
28. P. Castro Pena, Y.M. Kirova, and F. Campana Anatomical, clinical and radiological delineation of target volumes in breast cancer radiotherapy planning: individual variability, questions and answers Br J Radiol 82 979 2009 595 599
29. Y.M. Kirova, P. Castro Pena, and R. Dendale Simplified rules for everyday delineation of lymph node areas for breast cancer radiotherapy Br J Radiol 83 992 2010 683 686
30. M.S. Ewer, and E. Tan-Chiu Reversibility of trastuzumab cardiotoxicity: is the concept alive and well? J Clin Oncol 25 34 2007 5532 5533 author reply 5533-4
31. Y. Belkacemi, J. Gligorov, and M. Ozsahin Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study Ann Oncol 19 6 2008 1110 1116
32. Romestaing P, Hennequin C, Bosset JF, et al. Elective irradiation of Internal Mammary Chain (IMC) after mastectomy has no impact on 10y overall survival in breast cancer - results of a randomized phase III study in France. In: EBCC7; 2010; Barcelona, Spain: Eur J Cancer; 2010. p. 54.
33. O. Matzinger, I. Heimsoth, and P. Poortmans Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925) Acta Oncol 49 1 2010 24 34
34. I. Hojris, M. Overgaard, J.J. Christensen, and J. Overgaard Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danish Breast Cancer Cooperative Group Lancet 354 9188 1999 1425 1430
35. R. Shaffer, S. Tyldesley, M. Rolles, S. Chia, and I. Mohamed Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study Radiother Oncol 90 1 2009 122 126
36. M.A. Alm En-Din, J.R. Bellon, and E.A. Strom Radiation treatments may contribute to the development of cardiac dysfunction in breast cancer patients treated with chemotherapy and trastuzumab Int J Radiat Oncol Biol Phys 72 2008 S89 S90
37. Magne N, Chargari C, Macdermed D, et al. Tomorrow's targeted therapies in breast cancer patients: What is the risk for increased radiation-induced cardiac toxicity? Crit Rev Oncol Hematol, in press.
38. B. Zethelius, L. Berglund, and J. Sundstrom Use of multiple biomarkers to improve the prediction of death from cardiovascular causes N Engl J Med 358 20 2008 2107 2116
39. S.C. Darby, P. McGale, C.W. Taylor, and R. Peto Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300, 000 women in US SEER cancer registries Lancet Oncol 6 8 2005 557 565
40. N. Fournier-Bidoz, Y. Kirova, and F. Campana Technique alternatives for breast radiation oncology: conventional radiation therapy to tomotherapy J Med Phys 34 3 2009 149 152
41. J.R. Bellon, M.T. Gover, H.J. Burstein, J.R. Harris, and L.N. Harris Concurrent trastuzumab and radiation therapy (RT) in the adjuvant treatment of breast cancer Int J Radiat Oncol Biol Phys 63 2005 S55 S56
42. M.Y. Halyard, T.M. Pisansky, and A.C. Dueck Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831 J Clin Oncol 27 16 2009 2638 2644